Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies.

Dillinger, Thomas; Sheibani-Tezerji, Raheleh; Pulverer, Walter; Stelzer, Ines; Hassler, Melanie R.; Scheibelreiter, Janine; Pérez Malla, Carlos Uziel; Kuroll, Madeleine; Domazet, Sandra; Redl, Elisa; Ely, Sarah; Brezina, Stefanie; Tiefenbacher, Andreas; Rebhan, Katharina; Hübner, Nicolai; Grubmüller, Bernhard; Mitterhauser, Markus; Hacker, Marcus; Weinhaeusel, Andreas; Simon, Judit

To evaluate the potential of our identified marker genes in monitoring treatment response in mCRPC patients, we performed MSRE-qPCR analyses in liquid biopsies from mCRPC patients responsive ( I n i =17) or non-responsive ( I n i =12) to different therapies. When performing fragment analysis of a subset of benign, localized PCa and mCRPC plasma samples (n=20 per group), we observed a significant shift of the mean cfDNA fragment size from 175 bp in benign and localized PCa (range 168 - 183bp) to 168 bp in mCRPC (range 145 - 179 bp) samples (Figure S2I). DNA methylation markers differentiate treatment responsive from non-responsive patients Therapy options for mCRPC are diverse and evaluation of response to different treatments is thus essential for treatment decision making [[4]]. Classification results of mCRPC non-responder post-treatment vs. mCRPC responder post-treatment PMR-values from patients that underwent Abiraterone-acetate treatment.

CASTRATION-resistant prostate cancer; PROSTATE cancer; DNA methylation; TREATMENT effectiveness; CIRCULATING tumor DNA; BIOMARKERS; PROSTATE-specific antigen

Molecular Cancer, 2022, Vol 21, Issue 1, p1

1476-4598

Academic Journal

10.1186/s12943-021-01445-0